UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): June 1,
2021
MONOPAR
THERAPEUTICS INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-39070
|
|
32-0463781
|
(State or other
jurisdiction of incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
1000
Skokie Blvd., Suite 350, Wilmette,
IL 60091
|
|
60091
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
(847)
388-0349
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the
Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.001 par value
|
|
MNPR
|
|
The
Nasdaq Stock Market LLC
(Nasdaq Capital Market)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§ 240.12b-2 of this chapter).
Emerging growth
company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☒
Item
5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
Effective
June 1, 2021, Monopar Therapeutics Inc. (the “Company”)
appointed Andrew Cittadine, age 49, to serve as Chief Operating
Officer.
Mr.
Cittadine is an experienced healthcare executive and serial
entrepreneur with a successful track record of identifying,
founding, and building healthcare businesses from concept to
commercialization to acquisition by Fortune Global 1000
firms. Since 2011, Mr. Cittadine had served as Chief Executive
Officer of Diagnostic Photonics Inc, a venture capital backed
developer and manufacturer of advanced imaging systems for oncology
surgery and diagnostics. Prior to that,
he founded two successful diagnostic imaging companies, Sensant
Corp. and American Biooptics, and leading both through
acquisitions, by Siemens and Olympus, respectively. His
leadership experience also includes acting as
startup CEO of a critical care company, SonarMed, which was
acquired by Medtronic. He has managed manufacturing and quality
systems implementation, execution of multi-center clinical trials,
and regulatory clearances for new technologies in Europe and the
US. Mr. Cittadine received his BA, BS, and MS from Stanford and an
MBA from Northwestern’s Kellogg School of
Management. As previously announced, Mr. Cittadine has
been serving as a consultant to the Company over the past few
months to explore strategic and developmental options for
MNPR-101 as an intraoperative imaging agent in bladder cancer
surgery as well as other cancers.
In connection
with his appointment, Mr. Cittadine entered into the
Company’s standard form of executive employment agreement,
pursuant to which, among other things, he will receive an annual
base salary of $275,000, be eligible for an annual bonus target of
up to 35% of base salary and receive an initial grant of
100,000 stock options (subject to shareholder approval of
the amendments to the equity plan at the upcoming annual
meeting) that vest over four
years.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Monopar
Therapeutics Inc.
|
|
|
|
|
|
|
Date: June 1,
2021
|
By:
|
/s/
Kim
R. Tsuchimoto
|
|
|
|
Name: Kim
R. Tsuchimoto
|
|
|
|
Title:
Chief
Financial Officer, Secretary and Treasurer
|
|